The present disclosure relates to two crystalline monohydrates and twocrystalline anhydratesof gaboxadol:(see above formula)together with methods for preparing them.The present disclosure further relates to the use of crystalline forms ofgaboxadol for thetreatment of disorders susceptible of amelioration by GABA A receptor agonism.